| Number (%) |
---|---|
Total Number of Patients | 130 |
Age, years (median, range) | 74 (32–97) |
Sex (Male/Female) | 71 (54.6)/59 (45.4) |
Primary Cancer Site | |
 Lung | 31 (23.8) |
 Colon | 26 (20.0) |
 Pancreas | 12 (9.2) |
 Liver | 7 (5.4) |
 Stomach | 7 (5.4) |
 Esophagus | 5 (3.8) |
 Breast | 5 (3.8) |
 Ovary | 4 (3.1) |
 Uterine | 4 (3.1) |
 Prostate | 3 (2.3) |
 Other | 23 (17.7) |
 Unknown | 3 (2.3) |
Metastasis (total number) | |
 Liver | 54 (41.5) |
 Lung | 52 (40.0) |
 Bone | 40 (30.8) |
 Brain | 14 (10.8) |
PPS | |
  ≥ 70 | 20 (15.4) |
 40–60 | 74 (56.9) |
  ≤ 30 | 29 (22.3) |
 Unknown | 7 (5.4) |
Survival, days (median, range) n = 109 | 18 (2–193) |
QLQ-C15-PAL (median (Q1, Q3), mean (± SD)) | |
 Physical Functioning (n = 125) | 33.3 (20.0, 46.7), 37.0 ± 25.1 |
 Emotional Functioning (n = 129) | 66.7 (41.7, 83.3), 63.2 ± 28.3 |
 Dyspnea | 33.3 (0.0, 66.7), 39.5 ± 34.4 |
 Pain (n = 129) | 50.0 (16.7, 66.7), 47.3 ± 34.0 |
 Insomnia | 33.3 (0.0, 66.7), 40.0 ± 36.0 |
 Appetite Loss | 66.7 (33.3, 100), 57.7 ± 38.4 |
 Constipation (n = 128) | 33.3 (0.0, 66.7), 37.0 ± 35.3 |
 Fatigue (n = 129) | 66.7 (44.4, 100), 63.8 ± 29.7 |
 Nausea/Vomiting | 0.0 (0.0, 16.7), 18.7 ± 29.6 |
 QOL (n = 124) | 50.0 (16.7, 50.0), 38.7 ± 27.1 |
Inflammatory Biomarkers (median, range) n = 126 | |
 CRP (mg/dL) | 3.9 (<  0.1–32.1) |
 Alb (g/dL) | 2.6 (1.2–3.9) |
 NLR (n = 122) | 7.6 (0.6–187) |